Doxetasan

Doxetasan

docetaxel

Manufacturer:

Sanbe
Concise Prescribing Info
Contents
Docetaxel anhydrous
Indications/Uses
Breast cancer, Non-small cell lung cancer (NSCLC), ovarian cancer, prostate cancer.
Dosage/Direction for Use
Breast cancer Monotherapy: 100 mg/m2. In combination w/ doxorubicin: Docetaxel 75 mg/m2 + doxorubin 59 mg/m2. In combination w/ capecitabine: Docetaxel 75 mg/m2 3 wkly + capecitabine 1,250 mg/m2 twice daily for 2 wk followed by a 1-wk rest period. NSCLC Chemotherapy-naive patient Docetaxel 75 mg/m2 immediately followed by cisplatin 75 mg/m2 over 30-60 min. For treatment after failure of prior platinum-based therapy: 75 mg/m2 as a single agent. Prostate cancer Docetaxel 75 mg/m2 + prednisone or prednisolone 5 mg orally twice daily administered continuously.
Contraindications
Hypersensitivity. Baseline neutrophil count <1,500 cells/mm3; severe liver impairment. Pregnancy & lactation.
Special Precautions
Monitor complete blood count. Perform cardiac assessment before initiating docetaxel plus trastuzumab therapy. Monitor & treat symptoms of GI toxicity diarrhea w/ or w/o neutropenia.
Adverse Reactions
Neutropenia, hypersensitivity reactions, rash including localized eruptions mainly on the feet & hands, severe nail disorders, venous thromboembolic events, acute resp distress syndrome, interstitial pneumonia, pulmonary fibrosis, amenorrhea.
ATC Classification
L01CD02 - docetaxel ; Belongs to the class of plant alkaloids and other natural products, taxanes. Used in the treatment of cancer.
Presentation/Packing
Form
Doxetasan soln for infusion 80 mg/2 mL
Packing/Price
(+ 6 mL vial solvent ) 1's (Rp5,682,500/boks)
Form
Doxetasan soln for infusion 20 mg/0.5 mL
Packing/Price
(+ 1.5 mL vial solvent ) 1's (Rp1,948,300/boks)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in